Ingenium

Ingenium Therapeutics is a clinical-stage biotechnology company based in South Korea, specializing in the development of next-generation natural killer (NK) cell therapies for cancer. The company utilizes its proprietary Memory NK (mNK) cell platform to produce allogeneic NK cells with enhanced longevity, persistence, and anti-tumor activity compared to conventional NK cell products. Its lead candidate, IGN-NK, is currently being evaluated in Phase 2 clinical trials for Acute Myeloid Leukemia (AML) and is expanding into solid tumor indications such as Glioblastoma. Ingenium is also advancing a pipeline of CAR-NK therapies to address various hematological and solid malignancies. The company aims to provide off-the-shelf, scalable cell therapy solutions to overcome the limitations of current autologous treatments.